Basic Information
Ab Initio Biotherapeutics is an antigen discovery company. Its proprietary antigen discovery platform allows for the targeting of multi-transmembrane proteins, such as GPCRs, and facilitates the generation of antibodies related to various therapeutic indications, including neurological, cardiovascular, endocrine, and gastrointestinal diseases.
Ab Initio Biotherapeutics, Inc.
SanFrancisco,California,United States of America
less than 15 people
January 01, 2015
--
--